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Understanding the plaque
Coronary arteriosclerosis is a relatively benign chronic dis-
ease which carries a low mortality rate and, in most patients,
angina symptoms can be eliminated by medical treatment, per-
cutaneous coronary intervention (PCI) or coronary artery by-
pass grafting (CABG).
It is the occurrence of plaque rupture or erosion that trans-
forms arteriosclerosis from a stable condition into an acute se-
vere disease.  By exposing highly thrombogenic plaque mate-
rial to the circulation, plaque disruption provokes thrombosis
and acutely jeopardises blood flow3.  This is manifest clinically
as an ACS.  This term covers a number of clinical syndromes
that share physiopathological features and a worrisome prog-
nosis, and that can range from unstable angina and non-ST-
elevation myocardial infarction (NSTEMI) to ST-elevation myo-
cardial infarction (STEMI).
In recent years it has been learnt that whether the plaque
ruptures or not depends to a great extent on plaque morphol-
ogy rather than on the degree of stenosis, and particularly on
the nature of the plaque contents, especially its texture.  This
characteristic is in turn determined by a combination of three
elements: the capsule, the lipid content, and local and general
inflammatory processes.
Atherogenesis
Atherosclerosis is a chronic inflammatory disorder of the
arterial intima, characterized by recruitment of monocytes and
T lymphocytes and the induction of fibrosis with smooth muscle
cell proliferation and matrix synthesis4.  Literally, both soften-
ing and hardening are present in the mature atherosclerotic
plaque: a soft, hypocellular, lipid-rich core (athere- Greek for
porridge) walled off by a hard, fibrous capsule (skleros – Greek
for hard).
The culprit inflammatory insult in atherosclerosis appears
to be hypercholesterolaemia3.  The earliest events in the patho-
genesis of atherosclerosis are thought to be injury to the arte-
rial intima and oxidative modification of low-density lipopro-
tein (LDL) cholesterol in the subintimal space, which process is
catalysed by macrophages.
Plaque rupture
Advanced plaques give rise to thrombosis predominantly
through rupture of the plaque capsule with exposure of the
thrombogenic core to the circulation5.  Plaque rupture is prob-
ably the result of a dynamic interaction between intrinsic plaque
vulnerability and triggering mechanical forces imposed on the
plaque.  Surges in sympathetic activity with increase in blood
Abstract
The treatment of acute coronary syndromes in Malta has
been revolutionized over the past decade by the introduction of
the catheterization laboratory.  With the set-up of on-call car-
diac invasive teams for primary percutaneous coronary inter-
ventions in ST-elevation myocardial infarction, Malta may be
counted among the elite cardiac centres.  The recent comple-
tion of numerous multicentre international clinical trials has
led to an upheaval in the strategy and armamentarium for the
treatment of acute coronary syndromes.
Introduction
It has been a few years, or so one would like to think, since
the popular singer Paul McCartney wrote the song “The Long
and Winding Road”1.  There probably isn’t a better term that
could describe the development of the management of acute
coronary syndromes (ACS) in Malta over the past decade.
Coronary artery disease (CAD) is a leading cause of mor-
bidity and mortality worldwide.  Approximately 14 million in-
dividuals died of cardiovascular disease in 1990, and this is pro-
jected to rise to about 25 million by 20202.  It is a silent, pro-
gressive condition and the first presentation among one in two
patients is as myocardial infarction or sudden death.
The reduction in the incidence of premature cardiovascular
death is dependent on effective measures at risk factor modifi-
cation and aggressive management of ACS.  Progress in the
management of ACS has been dramatic in the past 5 years, fol-
lowing the completion of numerous large multicentre clinical
trials.
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pressure, heart rate and blood flow might be such triggers lead-
ing to plaque rupture.
Plaque vulnerability
The risk of plaque rupture seems to depend primarily on
plaque morphology rather than on plaque size or severity of
vessel stenosis.  Fibrosis with smooth muscle cell proliferation
and collagen synthesis hardens the plaque, stabilizing it against
rupture, whereas inflammation leading to degradation of the
fibrous cap and growth of the soft core predisposes the plaque
to rupture.
Platelet activation
Exposed matrix from the vessel wall and thrombin gener-
ated by the activation of the coagulation cascade, along with
circulating agonists such as adenosine diphosphate (ADP), are
powerful platelet activators.  The glycoproteins on the platelet
membrane surface, the most abundant of which are the GPIIb/
IIIa receptors, serve as receptors for these adhesive proteins.
Current strategies in the treatment of STEMI
Patients who fall in this clinical category are those who
present with ongoing chest pain and persistent ST-segment el-
evation or new-onset left bundle branch block.  The underlying
pathophysiology is acute total coronary occlusion.
The target of treatment of STEMI is to restore infarct artery
patency in the shortest possible time.  The candidates for initial
reperfusion efforts are:  (i) PCI, (ii) pharmacological and (iii)
combinations of both (facilitated PCI).
Percutaneous Coronary Intervention
PCI, when performed with minimal delay, is presently the
reperfusion technique leading to the best clinical outcome, ow-
ing to higher rates of restoring normal infarct artery flow when
compared with pharmacological reperfusion regimens (Fig.1).
Failure to achieve complete and sustained reperfusion can be
expected in up to 50% of thrombolysis treated patients.  Fur-
thermore, thrombolytic therapy is still associated with rates of
intracerebral haemorrhage of up to 1% especially when its use
is extended to the elderly and those suffering from hyperten-
sion.
PCI would be the preferred strategy were it not associated
with substantial pre-procedure delays.  Since there is a consid-
erable loss of efficacy when “door to balloon” time exceeds 90
minutes, our on-call cardiac invasive service is limited to ante-
rior STEMI patients who present at emergency department
within 4 hours of the onset of chest pain.
Pharmacological therapy – historical context
The benefits of streptokinase in STEMI were first revealed
by the GISSI trial in 19866.  The advantages of adjunctive therapy
in thrombolysis was then established in 1988, when the ISIS-2
study demonstrated that streptokinase and aspirin indepen-
dently reduced mortality, but had synergistic effect when com-
bined7.  ISIS-2 confirmed the benefit of thrombolysis in STEMI,
and established the critical role of adjunctive antiplatelet therapy
in this context.
Five years later, the GUSTO-1 trial showed that treatment
with accelerated infusion of tissue-plasminogen activator
(alteplase) in combination with unfractionated heparin resulted
in lower mortality among STEMI patients than treatment with
streptokinase in combination with either intravenous or sub-
cutaneous heparin8.  GUSTO-1 demonstrated that maximizing
the efficacy of a thrombolytic strategy depended on appropri-
ate adjunctive antithrombin therapy.
New recombinant agents may provide faster and sustained
thrombolysis with bolus administration.  In 1999, ASSENT-2
demonstrated that a single bolus of the more fibrin-specific
tenecteplase (TNK-tPA) was as safe and effective as front-loaded
alteplase9.  In fact, the use of weight-optimized tenecteplase low-
ered the risk of intracranial haemorrhage especially in elderly
female patients of low body weight.
Although the addition of GPIIb/IIIa receptor antagonists
to thrombolytic therapy was expected to enhance the rate and
extent of thrombolysis, the results of two major trials published
during 2001 show otherwise.  The combination of half-dose lytic,
tenecteplase in ASSENT-3 and reteplase in GUSTO-V, and the
GPIIb/IIIa receptor antagonist abciximab, yielded either only
marginal benefit or none at all in terms of early infarct-related
artery patency.  In terms of 30-day and 1-year mortality there
was no benefit whatsoever 10,11.
Current local scenario in pharmacological reperfusion
The current local scenario in pharmacological reperfusion
corresponds very closely to the results of the GRACE registry 12.
GRACE is a prospective, multinational registry enrolling pa-
tients with the full spectrum of ACS.  It has shown that in terms
of STEMI, fibrinolysis remains the most important means of
reperfusion: 43% receiving fibrinolysis, 13% primary PCI, 6%
both and a surprising 38% of patients eligible for reperfusion
therapy not receiving it at all.  Fibrinolysis is administered most
often in the coronary care unit (58%) or in the emergency de-
partment (39%).  Streptokinase is the most frequently used
agent (46%) followed by alteplase (40%).
Combination – facilitated PCI
Algorithms incorporating both fibrinolytics and PCI (facili-
tated PCI) are based on reports consistently showing better
outcome when the infarct related artery exhibits some pre-in-
tervention antegrade flow and on reports regarding the down-
side of increasing delays to PCI.  Preliminary results show that
such combinations are feasible and safe.
Treatment of non-ST elevation ACS
The primary aims of therapy for unstable angina or NSTEMI
are to relieve ischaemia and symptoms, to monitor the patient’s
condition using serial electrocardiograms and repeat measure-
ments of markers of myocardial necrosis and to initiate appro-
priate therapy to prevent further coronary thrombosis 13.
Intracoronary thrombosis plays a major role in ACS.
Thrombus formation may be reduced and thrombus resolution
facilitated by (i) drugs which inhibit thrombin: unfractionated
heparin (UFH) or low-molecular weight heparin (LMWH) and
(ii) antiplatelet agents: aspirin, ticlopidine, clopidogrel, GPIIb/
IIIa receptor blockers.
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Low molecular weight heparin
Clinical trials involving patients with unstable angina and
NSTEMI have shown that LMWHs are equivalent or superior
to conventional UFH for the prevention of ischaemic events,
and are safe and well-tolerated.  In addition, the use of LMWHs
eliminates the need for continuous intravenous infusion, anti-
coagulation monitoring and dosage adjustments associated with
UFH.
The benefit of LMWH over placebo in the presence of
aspirin has been demonstrated in the FRISC trial testing
dalteparin against placebo in aspirin-treated patients with un-
stable angina / NSTEMI14.  Several studies have been performed
to compare various preparations of LMWH given subcutane-
ously with intravenous standard UFH guided by aPTT values.
Enoxaparin proved to be superior in the ESSENCE and TIMI
11B studies15.
Thienopyridines: The new oral antiplatelet agents
The thienopyridines - ticlopidine and clopidogrel act by in-
hibiting binding of adenosine 5-diphosphate (ADP) to its re-
ceptors in platelets, resulting in inhibition of platelet aggrega-
tion.
However, the FANTASTIC trial revealed an important limi-
tation of therapy with ticlopidine since it takes between 5 to 7
days to achieve maximal platelet inhibition16.  The trial indi-
cates that when ticlopidine is first initiated on the day of stent
placement, as it frequently is in clinical practice, it appears to
provide insufficient antiplatelet inhibition for at least the first
24 hours after stent placement. Furthermore, intolerance to
ticlopidine is relatively frequent because of gastrointestinal dis-
orders or allergic reactions in 20%, neutropenia which can be
life-threatening in 1 to 3% and thrombocytopenia in 0.03%.  For
these reasons, ticlopidine has been superseded by clopidogrel13.
Clopidogrel has been investigated in aspirin-treated ACS
patients in the large landmark CURE study involving 12,562
patients17.  This demonstrated that initiating therapy with
clopidogrel early, on top of standard treatment including aspi-
rin, and continuing its use long-term for a median of 9 months,
significantly reduces the risk of cardiovascular death, non-fatal
myocardial infarction or stroke from 11.4% to 9.3%.  These find-
ings suggest that in practice, clopidogrel therapy should be
started immediately and continued long-term in ACS patients
irrespective of other treatment they may receive13.
Glycoprotein IIb/IIIa receptor inhibitors
The platelet glycoprotein IIb/IIIa receptor is the key path-
way leading to platelet aggregation.  There has been a prolifera-
tion of intravenously administered drugs that block the GPIIb/
IIIa receptor with a large number of large-scale randomized,
placebo-controlled drug trials involving over 34,000 patients.
In patients undergoing PCI, concomitant administra-
tion of GPIIb/IIIa receptor blockers consistently reduces throm-
botic complications, in particular periprocedural myocardial
infarction (EPIC18, CAPTURE19, EPILOG20, EPISTENT 21, RE-
STORE22, IMPACTII23, ESPRIT24 trials).  The combined end-
point of death, myocardial infarction and target vessel re-inter-
vention was significantly reduced in most of these studies.  In
view of these findings, treatment with a GPIIb/IIIa recpetor
blocker is recommended in all patients with ACS undergoing
PCI13 .  The infusion should be continued for 12 hours
(abciximab) or 24 hours (eptifibatide, tirofiban) after the pro-
cedure.
The approach of early intervention with stenting and
abciximab in patients with ACS was highly effective in the
EPISTENT trial, with a 47% reduction in death or large myo-
cardial infarction at 6 months seen with the combination of
stenting and abciximab compared with stenting alone (4% stent
and abciximab vs 9.5% stent and placebo)21.  In fact, combina-
tion therapies of GPIIb/IIIa receptor blockade and PCI may be
the key to unravelling the apparent paradox that early invasive
therapy after presentation with unstable angina / NSTEMI is
deleterious as suggested in the earlier VANQWISH  and OASIS
trials25,26.  These trials fail to reflect contemporary practice of
concomitant administration of intravenous GPIIb/IIIa recep-
tor blockers during PCI.
Coronary revascularization
Revascularization, either PCI or CABG, for unstable CAD is
performed to treat recurrent or ongoing myocardial ischaemia
and to avoid progression to myocardial infarction or death.  The
indications for myocardial revascularization and the preferred
approach depend on the extent and angiographic characteris-
tics of the lesions identified by coronary angiography.  Coro-
nary angiography remains the sole examination able to deter-
mine the presence and assess the extent of significant coronary
disease.
PCI is playing an increasingly important role in the man-
agement of unstable angina and NSTEMI, now that its safety
and success has been markedly improved with the use of stenting
and administration of GPIIb/IIIa receptor inhibitors.
The long and winding road
The introduction of the catheterization laboratory in Malta
has brought about a dramatic improvement in the care of ACS
patients over the past decade.  Not only is primary PCI avail-
able around the clock for patients with anterior STEMI who
present early, but coronary angiography is performed promptly
in patients with unstable angina and NSTEMI and this is regu-
larly followed up with the necessary revascularization proce-
dure.
The way forward
It should be appreciated that the management of ACS is an
exciting and rapidly moving field and therefore constant up-
grading of facilities and procedures is essential if better stan-
dards of care are to be achieved.
Given the importance of the time factor, there must be an
emphasis on immediate ambulance response with prehospital
and emergency department administration of lytic therapy.  This
is in contrast with coronary care unit administration and aims
at earlier reperfusion in STEMI patients.  Ambulance staff well-
trained in basic life-support techniques and in the use of auto-
mated external defibrillators will help save lives27.
Biochemical markers of myocardial necrosis, with troponin
being preferred to CK-MB, are fundamental in the diagnosis of
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ACS if the appropriate treatment strategy is to be implemented
at an early stage13.  These tests need to be reliable and readily
accessible.
New treatment modalities for ACS continue to enter the
clinical arena.  It is now clear that control of the pivotal platelet
thrombus will endure as a fundamental principle in the man-
agement of ACS.
The new antithrombotic and antiplatelet agents need to be
available for achieving today’s standard of care in ACS.  These
together with agents as disparate as angiotensin converting
enzyme inhibitors, angiotensin receptor blockers and statins will
all need to be fitted in with beta-blockers, nitrates and aspirin
Diagram A:  Coronary angiogram showing occluded left
anterior descending (LAD) coronary artery in patient with ex-
tensive acute anterior STEMI.
Diagram B:  Widely patent LAD after primary PCI.
Diagram C:   Left ventriculogram showing extensive antero-
lateral and apical akinesia prior to primary PCI.
Diagram D:  Akinesia limited to small  apical segment 10
months post primary PCI.
to tailor the most effective treatment strategy for an individual
ACS patient.
Where is the road leading to?
The past decade has brought new interventional treatment
modalities for patients with ACS in Malta.  The future holds the
exciting prospect of introducing new pharmacological treatment
strategies both as back-up for PCI and as stand-alone therapy.
We have embarked on the long and winding road that leads to
an improvement in survival and a reduction in long-term
morbidity from ACS.
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